Evidence map›Paper›PMID 40624393›Full record

ReviewMolecular biology reports2025

Exploring protein adenylyltransferase as a therapeutic target for combating ESKAPE pathogens in hospital-acquired infections.

Reabetswe Maake, Sarah Otun, Ikechukwu Achilonu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Reabetswe MaakeProtein Structure‑Function and Research Laboratory, Faculty of Science, School of Molecular and Cell Biology, University of the Witwatersrand, Braamfontein, Johannesburg, 2050, South Africa.
Sarah OtunProtein Structure‑Function and Research Laboratory, Faculty of Science, School of Molecular and Cell Biology, University of the Witwatersrand, Braamfontein, Johannesburg, 2050, South Africa.
Ikechukwu AchilonuProtein Structure‑Function and Research Laboratory, Faculty of Science, School of Molecular and Cell Biology, University of the Witwatersrand, Braamfontein, Johannesburg, 2050, South Africa. Ikechukwu.Achilonu@wits.ac.za.

Funding

NRF CPRR23042899244
6 · The paper itself

Abstract

introductionIn the face of increasing antimicrobial resistance, ESKAPE pathogens-Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species-pose a significant threat to public health, particularly in nosocomial settings. AREAS COVERED: This review explores the potential of targeting protein adenylyltransferase (PrAT) as a therapeutic strategy against these multidrug-resistant bacteria. We discuss the mechanisms of PrAT activity, its involvement in reduction-oxidation (redox) homeostasis, and the rationale for its potential as a drug target against ESKAPE pathogens. EXPERT OPINION: PrAT plays an essential role in sustaining the bacterium's redox homeostasis, a vital aspect of bacterial survival, by interacting with glutaredoxin (Grx). Future research should focus on elucidating the specific role of PrAT in ESKAPE pathogens, with an emphasis on studying the enzyme's function and designing targeted inhibitors. This review underscores the importance of continued investigation into PrAT in ESKAPE pathogens as a critical step in addressing the challenges of antimicrobial resistance in clinical practice.

Indexed as

Cross InfectionNucleotidyltransferasesAnti-Bacterial AgentsBacteriaBacterial ProteinsDrug Resistance, Multiple, BacterialHumansOxidation-ReductionAnti-Bacterial AgentsBacterial ProteinsNucleotidyltransferasesAMPylationAntimicrobial resistanceDeglutathionylationESKAPE pathogensGlutaredoxinGlutathioneGlutathionylationHospital-acquired infectionsProtein adenylyltransferase

Identifiers

PMID40624393
PMCPMC12234641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.